Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.48 |
| ▸ | JUN | P05412 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17529419 | 0.95 | KMT2A (0.56) | KMT2AKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL9688458 | 0.93 | KMT2A (0.46) | KMT2AKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL9688454 | 0.93 | KMT2A (0.46) | KMT2AKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL2553988 | 0.88 | KDM4E (0.69) | KMT2AKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL9553571 | 0.88 | FDPS (0.61) | KMT2AKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL2553992 | 0.88 | KDM4E (0.69) | KMT2AKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL14342653 | 0.88 | FDPS (0.61) | KMT2AKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL30656553 | 0.88 | KDM4E (0.69) | KMT2AKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL30448694 | 0.87 | KDM4E (0.57) | KMT2AKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL23665036 | 0.86 | KMT2A (0.54) | KMT2AKDM4EALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643428-B2 | Therapeutic drug for neurodegenerative disease and application thereof | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| US-11643428-B2 | Therapeutic drug for neurodegenerative disease and application thereof | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| WO-2021143812-A1 | METHOD FOR PREPARING N-(β-L-RHAMNOPYRANOSYL)FERULAMIDE AND USE THEREOF | 上海医药集团股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| US-20210087214-A1 | THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASE AND APPLICATION THEREOF | SHANGHAI DONGXI ZHIHUI BIOLOGICAL MEDICINE CO., LTD. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3750904-A1 | THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASE AND APPLICATION THEREOF | Shanghai Dongxi Zhihui Biological Medicine Co., Ltd. (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154195-A1 | THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASE AND APPLICATION THEREOF | 上海东西智荟生物医药有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-9878977-B2 | N-((3,4,5-trimethoxystyryl)aryl)cinnamamide compounds as potential anticancer agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-01-30 | — | — | US | disclosed |
| US-9878977-B2 | N-((3,4,5-trimethoxystyryl)aryl)cinnamamide compounds as potential anticancer agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-01-30 | — | — | US | disclosed |
| US-20170240503-A1 | N-((3,4,5-TRIMETHOXYSTYRYL)ARYL)CINNAMAMIDE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2017-08-24 | — | — | US | disclosed |
| US-20170240503-A1 | N-((3,4,5-TRIMETHOXYSTYRYL)ARYL)CINNAMAMIDE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2017-08-24 | — | — | US | disclosed |
| WO-2016027282-A1 | N-((3,4,5-TRIMETHOXYSTYRYL)ARYL)CINNAMAMIDE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643428-B2 | Therapeutic drug for neurodegenerative disease and application thereof | NES, GAP43, NLN | KMT2A 3566/4885KDM4E 3114/4885ALDH1A1 202/4885 |
| US-20170240503-A1 | N-((3,4,5-TRIMETHOXYSTYRYL)ARYL)CINNAMAMIDE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP51A1, CBR3 | KMT2A 832/4885KDM4E 673/4885ALDH1A1 224/4885 |
| US-20210087214-A1 | THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASE AND APPLICATION THEREOF | NES, GAP43, NLN | KMT2A 3566/4885KDM4E 3114/4885ALDH1A1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.